Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > TAB3(Gene name) > Human
  • Add your favorite
  • TAB3 (Gene name),
  • TGF-beta-activated kinase 1 and MAP3K7-binding protein 3 (Protein name ),  TAB3_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    TAB3(MAP3K7IP3);
    Protein name:
    TGF-beta-activated kinase 1 and MAP3K7-binding protein 3;
    Alternative:
    NF-kappa-B-activating protein 1;Mitogen-activated protein kinase kinase kinase 7-interacting protein 3;TGF-beta-activated kinase 1-binding protein 3;TAK1-binding protein 3(TAB-3);
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Interacts with TAB1, TAB2, MAP3K7, TRAF2 and TRAF6. The minimal TAB3-containing complex (TAB1-MAP3K7-TAB3) appears not to contain TAB2. However, it seems sensible to consider that TAB2 may also join this complex and may act in a cooperative manner with TAB3. Interacts with WDR34 (via the WD domains). Interacts with RBCK1.
    Function:
    Adapter linking MAP3K7/TAK1 and TRAF6 or TRAF2. Mediator of MAP3K7 activation, respectively in the IL1 and TNF signaling pathways. Plays a role in activation of NF-kappa-B and AP1 transcription factor. Isoform 2 may be an oncogenic factor.
    Subcellular Location:
    N/A
    Protein Attributes:
    Sequence length:
    712
    Sequence:
    50:
    MAQSSPQLDI | QVLHDLRQRF | PEIPEGVVSQ | CMLQNNNNLE | ACCRALSQES | 
    100:
    SKYLYMEYHS | PDDNRMNRNR | LLHINLGIHS | PSSYHPGDGA | QLNGGRTLVH | 
    150:
    SSSDGHIDPQ | HAAGKQLICL | VQEPHSAPAV | VAATPNYNPF | FMNEQNRSAA | 
    200:
    TPPSQPPQQP | SSMQTGMNPS | AMQGPSPPPP | PPSYMHIPRY | STNPITVTVS | 
    250:
    QNLPSGQTVP | RALQILPQIP | SNLYGSPGSI | YIRQTSQSSS | GRQTPQSTPW | 
    300:
    QSSPQGPVPH | YSQRPLPVYP | HQQNYQPSQY | SPKQQQIPQS | AYHSPPPSQC | 
    350:
    PSPFSSPQHQ | VQPSQLGHIF | MPPSPSTTPP | HPYQQGPPSY | QKQGSHSVAY | 
    400:
    LPYTASSLSK | GSMKKIEITV | EPSQRPGTAI | NRSPSPISNQ | PSPWNQHSLY | 
    450:
    TATTPPSSSP | SRGISSQPKP | PFSVNPVYIT | YTQPTGPSCT | PSPSPRVIPN | 
    500:
    PTTVFKITVG | RATTENLLNL | VDQEERSAAP | EPIQPISVIP | GSGGEKGSHK | 
    550:
    YQRSSSSGSD | DYAYTQALLL | HQRARMERLA | KQLKLEKEEL | ERLKSEVNGM | 
    600:
    EHDLMQRRLR | RVSCTTAIPT | PEEMTRLRSM | NRQLQINVDC | TLKEVDLLQS | 
    650:
    RGNFDPKAMN | NFYDNIEPGP | VVPPKPSKKD | SSDPCTIERK | ARRISVTSKV | 
    700:
    QADIHDTQAA | AADEHRTGST | QSPRTQPRDE | DYEGAPWNCD | SCTFLNHPAL | 
    712:
    NRCEQCEMPR | YT
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    String:
    Pfam:
    SMR:
    UniGene:
    MIM:
    Uniprot:
     
    FOR
    ELISA Kit for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Cat.:
    E2881h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Cat.:
    E2881m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Cat.:
    U2881h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Cat.:
    U2881m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Cat.:
    P2881Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Cat.:
    P2881Rb-m
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Monoclonal Antibody for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Monoclonal Antibody for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Protein for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3
    Protein for Human TGF-beta-activated kinase 1 and MAP3K7-binding protein 3

    R&D Technical Data
    s
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision

    Intra-assay Precision (Precision within an assay):Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

    Intra-Assay CV: ≤3.9%

    Inter-assay Precision (Precision between assays):Three samples of known concentration were tested in five separate assays to assess inter-assay precision.

    Inter-Assay CV: ≤7.7%

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery

    Recovery was determined by spiking various levels of ACE into serum and plasma .

    Sample Type

    Average(%)

    Recovery Range(%)

    Serum

    99

    91-103

    Plasma

    98

    93-106

     

     

     

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity

     

    The linearity of the kit was assayed by testing samples spiked with appropriate concentration of ACE and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.  

     

    Sample

    1:2

    1:4

    1:8

    1:16

    serum(n=5)

    92-105%

    90-101%

    95-105%

    92-109%

    EDTA plasma(n=5)

    89-95%

    93105%

    89-94%

    90-106%

    heparin plasma(n=5)

    93-104%

     

    94-110%

    101-111%

    91-110%

     

    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling."
      Ishitani T. , Takaesu G. , Ninomiya-Tsuji J. , Shibuya H. , Gaynor R.B. , Matsumoto K.
      EMBO J.22:6277-6288(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1);INTERACTION WITH MAP3K7; TRAF2 AND TRAF6;UBIQUITINATION;PHOSPHORYLATION;FUNCTION;VARIANT ARG-394
      tissue: Kidney.
    2. 2.
      "TAB3, a new binding partner of the protein kinase TAK1."
      Cheung P.C. , Nebreda A.R. , Cohen P.
      Biochem. J.378:27-34(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1);TISSUE SPECIFICITY;PHOSPHORYLATION;INTERACTION WITH TAB1; TAB2 AND MAP3K7;VARIANT ARG-394
    3. 3.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2);INTERACTION WITH MAP3K7 AND TRAF6;TISSUE SPECIFICITY;FUNCTION;VARIANT ARG-394
    4. 4.
      "The DNA sequence of the human X chromosome."
      Ross M.T. , Grafham D.V. , Coffey A.J. , Scherer S. , McLay K. , Muzny D. , Platzer M. , Howell G.R. , Burrows C. , Bird C.P. , Frankish A. , Lovell F.L. , Howe K.L. , Ashurst J.L. , Fulton R.S. , Sudbrak R. , Wen G. , Jones M.C. , more...
      Nature434:325-337(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    5. 5.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1);VARIANT ARG-394
      tissue: Eye.
    6. 6.
      "RBCK1 negatively regulates tumor necrosis factor- and interleukin-1-triggered NF-kappaB activation by targeting TAB2/3 for degradation."
      Tian Y. , Zhang Y. , Zhong B. , Wang Y.Y. , Diao F.C. , Wang R.P. , Zhang M. , Chen D.Y. , Zhai Z.H. , Shu H.B.
      J. Biol. Chem.282:16776-16782(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH RBCK1
    7. 7.
      "Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex."
      Mendoza H. , Campbell D.G. , Burness K. , Hastie J. , Ronkina N. , Shim J.H. , Arthur J.S. , Davis R.J. , Gaestel M. , Johnson G.L. , Ghosh S. , Cohen P.
      Biochem. J.409:711-722(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION AT SER-506
    8. 8.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60; THR-404 AND SER-492;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    9. 9.
      "WDR34 is a novel TAK1-associated suppressor of the IL-1R/TLR3/TLR4-induced NF-kappaB activation pathway."
      Gao D. , Wang R. , Li B. , Yang Y. , Zhai Z. , Chen D.Y.
      Cell. Mol. Life Sci.66:2573-2584(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH WDR34
    10. 10.
      "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."
      Olsen J.V. , Vermeulen M. , Santamaria A. , Kumar C. , Miller M.L. , Jensen L.J. , Gnad F. , Cox J. , Jensen T.S. , Nigg E.A. , Brunak S. , Mann M.
      Sci. Signal.3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2;PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60;IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS];CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    11. 11.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH TRIM5
    Product Feedback Wall
    Hot Genes
    Top Searches
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.com.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    鄂ICP备10015095号-1

    鄂公网安备 42018502005535号

    Twitter